<div id="readability-page-1"><p><span>Sanofi (NASDAQ:SNY - Get Free Report)</span> was upgraded by equities researchers at StockNews.com from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report issued to clients and investors on Tuesday.</p><ul><li>Novo Nordisk Arms Wegovy to Be a Triple Threat </li></ul><p>Separately, Argus increased their price objective on Sanofi from $55.00 to $60.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 26th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $57.50.</p><p><b>View Our Latest Stock Report on Sanofi</b></p><h2>Sanofi Price Performance</h2><ul><li>6 reasons to buy Teva Pharmaceuticals stock sooner than later </li></ul><p>NASDAQ SNY traded up $1.27 on Tuesday, reaching $57.53. 3,561,640 shares of the stock traded hands, compared to its average volume of 2,086,575. The firm's fifty day simple moving average is $52.23 and its 200 day simple moving average is $49.60. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company has a market cap of $145.71 billion, a price-to-earnings ratio of 28.91, a P/E/G ratio of 1.60 and a beta of 0.60. Sanofi has a 12 month low of $42.63 and a 12 month high of $57.92. </p><p>Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.05. The business had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company's revenue was up 7.8% compared to the same quarter last year. During the same period last year, the company posted $0.95 EPS. As a group, research analysts predict that Sanofi will post 4.23 EPS for the current fiscal year. </p><h2>Institutional Investors Weigh In On Sanofi</h2><ul><li>20 best healthcare dividend stocks to invest in</li></ul><p>Institutional investors have recently added to or reduced their stakes in the stock. TCTC Holdings LLC raised its position in Sanofi by 28.0% in the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company's stock worth $47,000 after purchasing an additional 210 shares during the last quarter. HB Wealth Management LLC increased its position in shares of Sanofi by 3.7% in the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company's stock valued at $299,000 after buying an additional 221 shares in the last quarter. Wynn Capital LLC increased its position in shares of Sanofi by 4.5% in the 1st quarter. Wynn Capital LLC now owns 5,266 shares of the company's stock valued at $256,000 after buying an additional 226 shares in the last quarter. Insigneo Advisory Services LLC increased its position in shares of Sanofi by 3.3% in the 2nd quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company's stock valued at $371,000 after buying an additional 228 shares in the last quarter. Finally, Angeles Investment Advisors LLC increased its position in shares of Sanofi by 2.1% in the 4th quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company's stock valued at $598,000 after buying an additional 244 shares in the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds. </p><h2>About Sanofi</h2> (Get Free Report)<p>Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Sanofi</li><li>Stock Market Sectors: What Are They and How Many Are There? </li><li>3 Small Cap Stocks That Insiders Are Buying</li><li>What is the S&amp;P/TSX Index?</li><li>Analysts Forecast Big Upside for Western Digital—Don’t Miss Out</li><li>There Are Different Types of Stock To Invest In</li><li>3 Must-Own Stocks for Bullish Investors in Today's Market</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Tim Sykes’ Urgent Trade Alert: “Make this move now” <span><span>(From Timothy Sykes)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4"/></p><h2>Should you invest $1,000 in Sanofi right now?</h2><p>Before you consider Sanofi, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.</p><p>While Sanofi currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p> </div>

SNYNF

<p>Sanofi was upgraded from "buy" to "strong-buy" by StockNews.com. Additionally, Argus revised their price target for the stock, which is currently rated with a consensus of "Moderate Buy" by analysts. Trading volume reached over 3.5 million shares, with Sanofi's market capitalization at approximately $84.71 billion. The company reported a 7.8% increase in revenue year-over-year and beat earnings expectations for the quarter. Institutional investors have also been increasing their stakes in the company recently.</p>

Sanofi (NASDAQ:SNY) Raised to Strong-Buy at StockNews.com